ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 2 of 2-Diagnostic Criteria and Appropriate Utilization

Sharmila Dorbala; Yukio Ando; Sabahat Bokhari; Angela Dispenzieri; Rodney H Falk; Victor A Ferrari; Marianna Fontana; Olivier Gheysens; Julian D Gillmore; Andor W J M Glaudemans; Mazen A Hanna; Bouke P C Hazenberg; Arnt V Kristen; Raymond Y Kwong; Mathew S Maurer; Giampaolo Merlini; Edward J Miller; James C Moon; Venkatesh L Murthy; C Cristina Quarta; Claudio Rapezzi; Frederick L Ruberg; Sanjiv J Shah; Riemer H J A Slart; Hein J Verberne; Jamieson M Bourque

doi:10.1016/j.cardfail.2019.08.002

ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 2 of 2-Diagnostic Criteria and Appropriate Utilization

J Card Fail. 2019 Nov;25(11):854-865. doi: 10.1016/j.cardfail.2019.08.002. Epub 2019 Aug 29.

Authors

Sharmila Dorbala¹, Yukio Ando², Sabahat Bokhari³, Angela Dispenzieri⁴, Rodney H Falk⁵, Victor A Ferrari⁶, Marianna Fontana⁷, Olivier Gheysens⁸, Julian D Gillmore⁷, Andor W J M Glaudemans⁹, Mazen A Hanna¹⁰, Bouke P C Hazenberg¹¹, Arnt V Kristen¹², Raymond Y Kwong⁵, Mathew S Maurer³, Giampaolo Merlini¹³, Edward J Miller¹⁴, James C Moon⁷, Venkatesh L Murthy¹⁵, C Cristina Quarta⁷, Claudio Rapezzi¹⁶, Frederick L Ruberg¹⁷, Sanjiv J Shah¹⁸, Riemer H J A Slart⁹, Hein J Verberne¹⁹, Jamieson M Bourque²⁰

Affiliations

¹ Cardiac Amyloidosis Program, Cardiovascular Imaging Program, Departments of Radiology and Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts. Electronic address: sdorbala@bwh.harvard.edu.
² Department of Neurology, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan.
³ Columbia University Medical Center, Columbia University Medical Center/New York Presbyterian Hospital, Columbia University, New York, New York.
⁴ Divisions of Hematology and Cardiovascular Diseases, Department of Radiology, Division of Nuclear Medicine, Department of Medicine, Mayo Clinic, Rochester, Minnesota.
⁵ Cardiac Amyloidosis Program, Cardiovascular Imaging Program, Departments of Radiology and Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
⁶ Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
⁷ Division of Medicine, National Amyloidosis Centre, University College London, London, United Kingdom.
⁸ Nuclear Medicine and Molecular Imaging, University Hospitals Leuven, Leuven, Belgium.
⁹ Medical Imaging Center, Department of Nuclear Medicine and Molecular Imaging, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
¹⁰ Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio.
¹¹ Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
¹² Department of Cardiology, University of Heidelberg, Heidelberg, Germany.
¹³ Amyloidosis Research and Treatment Center, Foundation Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo, Pavia, Italy; Department of Molecular Medicine, University of Pavia, Pavia, Italy.
¹⁴ Cardiovascular Medicine, Yale University School of Medicine, New Haven, Connecticut.
¹⁵ Frankel Cardiovascular Center, Michigan Medicine, Ann Arbor, Michigan.
¹⁶ Cardiology Unit, Department of Experimental, Diagnostic and Specialty Medicine, Alma Mater-University of Bologna, Bologna, Italy.
¹⁷ Amyloidosis Center and Section of Cardiovascular Medicine, Department of Medicine, Boston University School of Medicine, Boston Medical Center, Boston, Massachusetts.
¹⁸ Feinberg School of Medicine, Northwestern University, Chicago, Illinois.
¹⁹ Department of Radiology and Nuclear Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
²⁰ Cardiovascular Imaging Center, Departments of Medicine and Radiology, University of Virginia, Charlottesville, Virginia.

PMID: 31473267
DOI: 10.1016/j.cardfail.2019.08.002

Abstract

Cardiac amyloidosis is emerging as an underdiagnosed cause of heart failure and mortality. Growing literature suggests that a noninvasive diagnosis of cardiac amyloidosis is now feasible. However, the diagnostic criteria and utilization of imaging in cardiac amyloidosis are not standardized. In this paper, Part 2 of a series, a panel of international experts from multiple societies define the diagnostic criteria for cardiac amyloidosis and appropriate utilization of echocardiography, cardiovascular magnetic resonance imaging, and radionuclide imaging in the evaluation of patients with known or suspected cardiac amyloidosis.

Keywords: Cardiac amyloidosis; appropriate use; diagnosis; expert consensus; multimodality.

Publication types

Review

MeSH terms

American Heart Association*
Amyloidosis / diagnostic imaging*
Amyloidosis / epidemiology
Amyloidosis / therapy
Cardiology / methods
Cardiology / standards*
Cardiomyopathies / diagnostic imaging*
Cardiomyopathies / epidemiology
Cardiomyopathies / therapy
Consensus
Echocardiography / methods
Echocardiography / standards
Heart Failure / diagnostic imaging
Heart Failure / epidemiology
Heart Failure / therapy
Humans
Magnetic Resonance Imaging, Cine / methods
Magnetic Resonance Imaging, Cine / standards
Molecular Imaging / methods
Molecular Imaging / standards
Multimodal Imaging / methods
Multimodal Imaging / standards*
Nuclear Medicine / methods
Nuclear Medicine / standards
Societies, Medical / standards*
Tomography, X-Ray Computed / methods
Tomography, X-Ray Computed / standards
United States / epidemiology

Abstract

Publication types

MeSH terms

Grants and funding